Share ownership cbdMD, Inc.

YCBD

US12482W4087

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:00 2026-05-15 pm EDT			5-day change	1st Jan Change
0.7672 ^USD	-5.32%		-8.67%	-43.17%

May. 14	CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026
May. 14	CbdMD reports 19% year-over-year and 12% sequential revenue growth	RE

Share class: cbdMD, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	10,497,919	9,374,720 ( 89.3 %)	0	89.3 %
Stock B	0	1,591,210	0	0

Major shareholders: cbdMD, Inc.

Name	Equities	%	Valuation
Jeffrey Porter 5.494 %	576,674	5.494 %	501 130 $
Crc Investment Fund LP 4.156 %	436,150	4.156 %	379 014 $
Worth Venture Partners LLC 1.761 %	184,796	1.761 %	160 588 $
UBS Financial Services, Inc. 1.569 %	164,643	1.569 %	143 075 $
CSS LLC 1.311 %	137,621	1.311 %	119 593 $
XTX Topco Ltd. 0.877 %	92,049	0.877 %	79 991 $
Chapin Davis, Inc. 0.7741 %	81,250	0.7741 %	70 606 $
Jane Street Group LLC 0.7273 %	76,338	0.7273 %	66 338 $
T. Kennedy 0.6548 %	68,722	0.6548 %	59 719 $
Alesco Advisors LLC 0.6528 %	68,513	0.6528 %	59 538 $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	7.35%
Individuals	6.66%
Other	5.77%
Unknown	80.22%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	12.24%
Individuals	6.66%
Cayman Islands	0.88%

Based on 1000 largest holdings

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company